Presight Capital

Presight Capital is an international venture capital firm founded in 2019 and based in West Hollywood, California. Founded by entrepreneur and investor Christian Angermayer, the firm focuses on early-stage investment opportunities across various sectors, including biotechnology, consumer technology, fintech, deep tech, food tech, cryptocurrency, and healthcare. Presight Capital primarily collaborates with a network of entrepreneurs and investors, leveraging their expertise and connections to identify promising ventures. The firm's main limited partner is Angermayer's family office, Apeiron. As a registered investment adviser, Presight Capital aims to support innovative companies that are poised for growth in cutting-edge industries.

Constantin Bisanz

Investor

Michael Ho

Investor

Marley Windham-Herman

Investor

59 past transactions

Duetti

Series A in 2023
Duetti is a music fintech company that offers financial solutions. The company works with independent musicians to purchase catalog rights and then monetizes them using data and social media marketing. It aims to get a wide range of artists quick access to catalog sales and unlock new investment opportunities. It also provides data-driven prices for established tracks, allowing artists to sell individual tracks or even parts thereof, then markets those tracks going forward using ROI-focused techniques.

Lilo

Pre Seed Round in 2022
Lilo is a leading invest-and-experience platform in Europe that facilitates fractional ownership of high-end residential properties in sought-after locations. By providing exclusive access to a curated selection of properties across popular European cities, Lilo allows users to purchase shares in these premium real estate assets. The platform enables members to split ownership into fractions, accommodating up to eight investors per property. This innovative approach allows individuals to build a diverse global property portfolio while minimizing the financial and logistical challenges typically associated with real estate investment.

Duetti

Seed Round in 2022
Duetti is a music fintech company that offers financial solutions. The company works with independent musicians to purchase catalog rights and then monetizes them using data and social media marketing. It aims to get a wide range of artists quick access to catalog sales and unlock new investment opportunities. It also provides data-driven prices for established tracks, allowing artists to sell individual tracks or even parts thereof, then markets those tracks going forward using ROI-focused techniques.

Bamba

Seed Round in 2022
Bamba is an Android application designed to assist micro-merchants in Africa in managing their businesses using mobile technology. The application provides essential tools that enable merchants to handle customer management, facilitate payments, and access cash advances based on their future cash flow. Additionally, Bamba's software allows users to record stock levels, enhancing their operational efficiency. By offering these comprehensive services, Bamba empowers micro-merchants to streamline their business processes and improve financial management directly from their smartphones.

Rario

Series A in 2022
RARIO is a non-fungible token (NFT) marketplace that makes the digital collectible revolution accessible to every fan. The company was founded in 2021 and is based in Singapore.

Centenara Labs

Angel Round in 2022
Centenara Labs is a biotechnology company that focuses on developing innovative drug therapies aimed at improving and prolonging human lifespan. Founded in 2019 and headquartered in Zug, Switzerland, the company invests in research and technologies that target age-related diseases. Centenara Labs operates as a fully integrated platform, providing a range of services including drug discovery expertise, financial support, and administrative services. Its mission is to advance scientific understanding and create effective solutions that enable individuals to experience healthier and longer lives.

Alaan

Seed Round in 2022
Alaan is a multi-currency spend management platform enabling SMEs to digitise their business expenses by providing employees with corporate cards to make company purchases and automating the invoicing process.

Cloud Paper

Venture Round in 2022
Cloud Paper, Inc. is a Seattle-based manufacturer that produces toilet paper made entirely from 100% bamboo. Founded in 2019, the company aims to address environmental concerns associated with the traditional paper industry by offering a tree-free alternative that does not harm trees. Their products are designed to be super-soft and are packaged using plastic-free and recycled materials, aligning with their commitment to sustainability. Cloud Paper sells its eco-friendly toilet paper through its website, promoting a solution to deforestation while providing a high-quality consumer product.

Nana Delivery

Pre Seed Round in 2022
Operator of an online retail platform designed to deliver groceries in less time. The company installs dark stores across the cities and offers a wide variety of products and carefully selects the products and delivers them, enabling consumers to get access to a quick and cheaper grocery shopping experience.

Denario

Seed Round in 2022
Denario is a Berlin-based payments processor startup.

Koniku

Series A in 2021
Koniku is the world's first Neurocomputation company. We start with a premise that the human brain is the most powerful computer ever devised. We show that capturing that computational power is an engineering problem. Koniku proceeds to meet that challenge with clear solutions. We have built a neurochip with actual biological neurons. This chip is capable of sensing particles in parts per trillion using only 64 neurons. Such sensitivity is unprecedented. Its our intention to expand on the number neurons we have on our device just like traditional silicon processors. Eventually we will have millions of neurons per chip. Only with such a device is true cognitive computation possible - AI. We are shipping our fist devices at the end of the year. Koniku is also working on developing COVID-sniffing robots as a fast testing alternative.

thirdweb

Seed Round in 2021
thirdweb is an end to end developer tool accelerating teams building web3 apps, games, tokens, NFTs, marketplaces, DAOs and more. It provides powerful SDKs for developers and enables them to build web3 apps, and deploy custom or pre-built smart contracts. It was founded in 2020 by Furqan Rydhan and Steven Bartlett and is based in San Francisco, California, United States.

Peek

Series C in 2021
Peek is a travel activities marketplace based in San Francisco, California, that simplifies the process of discovering and booking tours and activities throughout the United States. Founded in 2011, the company provides a technology platform that connects travelers with a variety of experiences, facilitating easy online bookings. Peek's offerings include a comprehensive selection of tours and lessons, curated by handpicked vendors and experts to cater to diverse travel preferences. Through its website and mobile app, Peek generates new customers and enhances the visibility of local operators, empowering them to manage and grow their businesses effectively.

Velocity

Series A in 2021
Provider of banking and financial services intended to fund companies or offer credit based on their sales. The company provides a range of financial services including term loans, revenue-based financing, overdrafts, payments as well as analytics for businesses with zero equity dilution or personal guarantees, enabling clients to avail an alternative to venture capital or loan where repayments happen as a fixed percentage of future revenues.

Lindus Health

Seed Round in 2021
Operator of an anti-contract research organization intended to deliver end-to-end clinical trials for health and biotech companies. The company's software allows access to electronic health records, design, patient recruitment, clinical data capture, monitoring, and project management, while reducing the risk of clinical trial failure, enabling health experts to accelerate clinician trials and improve patient treatment outcomes.

Grounded Foods Co.

Seed Round in 2021
Grounded Foods Co. specializes in producing plant-based cheeses crafted from cauliflower and hemp seeds. The company's product lineup includes gruyere-style cheese, camembert-style cheese, marinated hemp seed feta, and hemp seed cream cheese. Utilizing a proprietary fermentation process, Grounded Foods Co. transforms imperfect vegetables and hemp seeds into cheese alternatives that closely mimic the flavor and texture of traditional dairy cheese while offering high nutritional value and environmental benefits. Founded in 2019 by Australian entrepreneurs Veronica Fil and Shaun Quade, the company operates out of West Hollywood, California, and distributes its products through retail stores and online channels.

Delix

Series A in 2021
Developer of clinical-stage neuroscience therapeutics intended to harness novel neuroplasticity-promoting treatments for difficult-to-treat neuropsychiatric and neurological disorders. The company's compounds include non-hallucinogenic, non-psychotomimetic, and non-dissociative versions of psychedelic components, enabling healthcare service providers to address significant mental health challenges through phenotypic drug discovery across various chemotypes and mechanisms of action.

Delix

Series A in 2021
Developer of clinical-stage neuroscience therapeutics intended to harness novel neuroplasticity-promoting treatments for difficult-to-treat neuropsychiatric and neurological disorders. The company's compounds include non-hallucinogenic, non-psychotomimetic, and non-dissociative versions of psychedelic components, enabling healthcare service providers to address significant mental health challenges through phenotypic drug discovery across various chemotypes and mechanisms of action.

Upscalio

Series A in 2021
Upscalio is a financial services provider that invests in and supports digital brands selling on e-commerce platforms such as Amazon, Myntra, Flipkart, and Nykaa. The company specializes in managing essential operations for these brands, including multi-marketplace management, digital marketing, branding, logistics, sourcing, finance, and overall business operations. By leveraging advanced analytics, Upscalio helps e-commerce businesses enhance their performance and achieve their growth objectives.

Razor Group

Venture Round in 2021
Operator of a consumer goods holding company intended to invest and buy profitable brands. The company's marketplace combines advanced data analytics and custom-built technology, an optimized M&A process and in-house e-commerce and finance expertise to find suitable acquisition targets, enabling brands to scale profitable and demonstrate category leadership, better-quality products and customer reviews.

Penta

Series B in 2021
Penta Fintech Ltd. is a digital banking platform based in Berlin, Germany, specifically designed for startups and small to medium-sized enterprises (SMEs). Established in 2016, Penta aims to streamline banking processes for businesses by providing automated services such as bank account management and invoicing. The platform allows users to open a digital bank account quickly, typically within minutes, and offers cashless banking services that facilitate efficient cash flow management. With a mission to transform business banking in Europe and beyond, Penta focuses on helping its clients save time and money, thereby enhancing their overall banking experience.

Syfe

Series B in 2021
Syfe Pte. Ltd. is a digital investment manager based in Singapore that provides portfolio management, cash management, brokerage services, and wealth advisory. The firm focuses on creating customized, globally diversified portfolios for its clients by utilizing a proprietary algorithm that monitors and adjusts investments to optimize returns while managing risk. Syfe employs fundamental analysis to guide its investments in equity and fixed income markets worldwide. The platform aims to offer greater transparency and more efficient investment strategies, distinguishing itself from traditional investment management through the absence of high fees and hidden costs, ultimately striving for better investment outcomes for its clients.

Upscalio

Seed Round in 2021
Upscalio is a financial services provider that invests in and supports digital brands selling on e-commerce platforms such as Amazon, Myntra, Flipkart, and Nykaa. The company specializes in managing essential operations for these brands, including multi-marketplace management, digital marketing, branding, logistics, sourcing, finance, and overall business operations. By leveraging advanced analytics, Upscalio helps e-commerce businesses enhance their performance and achieve their growth objectives.

Umoja Biopharma

Series B in 2021
Provider of immunotherapies intended to transform cancer treatment and improve quality of life. The company's cellular immunotherapy platform uses gene therapy to target cancer cells and delivers to any patient, with any tumor, at any time to directly, safely, and controllably attack cancer, enabling medical practitioners to safeguard patients by creating and harnessing a powerful immune response in the body.

Opontia

Debt Financing in 2021
Opontia provides a fast and fair way for small e-commerce business owners to sell their companies. They buy businesses with a long-term competitive advantage and strong home-grown brands. They know that selling a business can be stressful and difficult, which is why they have streamlined the process so that you can receive money in your account within just 6 weeks of starting the process.

Opontia

Seed Round in 2021
Opontia provides a fast and fair way for small e-commerce business owners to sell their companies. They buy businesses with a long-term competitive advantage and strong home-grown brands. They know that selling a business can be stressful and difficult, which is why they have streamlined the process so that you can receive money in your account within just 6 weeks of starting the process.

Blackrock Neurotech

Venture Round in 2021
Blackrock Neurotech’s mission is to provide innovative tools and neurotech expertise to translate technology into a novel, implantable clinical solutions that improve human lives.

Una Brands

Debt Financing in 2021
Una Brands provide a fast and fair way for e-commerce business owners to sell their companies.

Una Brands

Seed Round in 2021
Una Brands provide a fast and fair way for e-commerce business owners to sell their companies.

Valoreo

Seed Round in 2021
Valoreo is an e-commerce holding company that specializes in acquiring, operating, and scaling successful e-commerce brands primarily in Latin America. The company focuses on brands with excellent customer reviews and proven success as top sellers in niche categories with high-growth potential. By consolidating outstanding startups that offer category-leading products, Valoreo enhances their operations and develops its own brands in-house. This strategy allows Valoreo to help its clients significantly scale their businesses and advance to the next stage of development.

Alto Neuroscience

Series A in 2021
Alto Neuroscience Inc is a clinical-stage biopharmaceutical company with a mission to redefine psychiatry by leveraging individuals' neurobiology to develop personalized and effective treatment options. The company currently consists of different clinical-stage assets such as ALTO-100, ALTO-202, ALTO-101, and ALTO-300 among others initially targeting depressive disorders and schizophrenia populations as identified by independent brain-based biomarkers.

Angiex

Series B in 2021
Angiex is a biotechnology company focused on developing vascular-targeted biotherapeutics for cancer treatment. Founded by leading scientists, the company specializes in antibody-drug conjugate therapies that address key aspects of endothelial biology, particularly angiogenesis. Angiex's lead product utilizes a novel approach to deliver therapeutic agents directly to the nucleus of tumor cells and to the activated endothelium of tumors and inflamed vessels. This innovative method aims to enhance the efficacy of treatments for various solid tumors, including pancreatic, lung, liver cancers, and glioblastoma multiforme. With intellectual property originating from Beth Israel Deaconess Medical Center, Angiex operates out of LabCentral in Cambridge, positioning itself at the forefront of cancer therapeutics.

Alloy Therapeutics

Series C in 2021
Alloy Therapeutics is a biotechnology company focused on enhancing drug discovery through accessible platforms and services. Founded in 2017 and based in Lexington, Massachusetts, the company offers Alloy-Gx, a comprehensive suite of immunocompetent transgenic mice that supports advanced human antibody discovery without royalty fees. This innovative platform aims to simplify and promote antibody discovery projects by providing broad, non-exclusive access to essential drug discovery tools. By democratizing these resources, Alloy Therapeutics enables scientists to pursue their antibody research more efficiently and effectively.

Velocity

Seed Round in 2021
Provider of banking and financial services intended to fund companies or offer credit based on their sales. The company provides a range of financial services including term loans, revenue-based financing, overdrafts, payments as well as analytics for businesses with zero equity dilution or personal guarantees, enabling clients to avail an alternative to venture capital or loan where repayments happen as a fixed percentage of future revenues.

Chemomab

Post in 2021
ChemomAb Ltd. is a clinical-stage biopharmaceutical company based in Tel Aviv, Israel, founded in 2011. The company focuses on developing proprietary monoclonal antibodies aimed at treating autoimmune, inflammatory, and fibrotic diseases, including rare conditions. Its leading therapeutic candidate, CM-101, has undergone extensive pre-clinical testing in animal models that simulate human disorders, demonstrating promising safety and efficacy along with a novel mechanism of action. Through its innovative approach, ChemomAb aims to address unmet medical needs in immune-mediated and fibrotic disorders.

Penta

Series B in 2021
Penta Fintech Ltd. is a digital banking platform based in Berlin, Germany, specifically designed for startups and small to medium-sized enterprises (SMEs). Established in 2016, Penta aims to streamline banking processes for businesses by providing automated services such as bank account management and invoicing. The platform allows users to open a digital bank account quickly, typically within minutes, and offers cashless banking services that facilitate efficient cash flow management. With a mission to transform business banking in Europe and beyond, Penta focuses on helping its clients save time and money, thereby enhancing their overall banking experience.

Valoreo

Seed Round in 2021
Valoreo is an e-commerce holding company that specializes in acquiring, operating, and scaling successful e-commerce brands primarily in Latin America. The company focuses on brands with excellent customer reviews and proven success as top sellers in niche categories with high-growth potential. By consolidating outstanding startups that offer category-leading products, Valoreo enhances their operations and develops its own brands in-house. This strategy allows Valoreo to help its clients significantly scale their businesses and advance to the next stage of development.

Hoxton Farms

Seed Round in 2021
Hoxton Farms, located in London, UK, specializes in producing real animal fat without the use of animals. The company employs a unique combination of cell biology and mathematical modeling to create cultivated fat, specifically designed as an ingredient for the meat alternatives industry. By utilizing a tissue culture system in bioreactors, Hoxton Farms offers purified animal fat that serves various sectors, including meat, bakery, confectionery, and cosmetics, thus providing a cruelty-free option for manufacturers seeking sustainable ingredients.

New Amsterdam Pharma

Series A in 2021
New Amsterdam Pharma B.V. is a clinical-stage biopharmaceutical company based in Naarden, the Netherlands, focused on researching and developing innovative therapies for cardio-metabolic diseases. Founded in 2019, the company is dedicated to improving patient care for those with metabolic disorders, particularly where existing treatments are inadequate or poorly tolerated. Its lead product, obicetrapib, is a next-generation oral CETP inhibitor designed to provide a preferred LDL cholesterol-lowering option for patients who experience statin intolerance or for those with Arteriosclerotic Cardiovascular Disease and Familial Hypercholesterolemia who are on maximally tolerated statin therapy.

Sensei Biotherapeutics

Series B in 2021
Sensei Biotherapeutics, Inc. develops precision cancer therapeutics that target a tumor-specific antigen (aspartate ß-hydroxylase). It offers various cancer immunotherapies, such as cancer vaccines and T-cell therapies for cancer patients. Sensei Biotherapeutics, Inc. was formerly known as Panacea Pharmaceuticals, Inc. The company was founded in 1999 and is based in Gaithersburg, Maryland with an additional office in Boston, Massachusetts.

Sensei Biotherapeutics

Series B in 2021
Sensei Biotherapeutics, Inc. develops precision cancer therapeutics that target a tumor-specific antigen (aspartate ß-hydroxylase). It offers various cancer immunotherapies, such as cancer vaccines and T-cell therapies for cancer patients. Sensei Biotherapeutics, Inc. was formerly known as Panacea Pharmaceuticals, Inc. The company was founded in 1999 and is based in Gaithersburg, Maryland with an additional office in Boston, Massachusetts.

Peptilogics

Series B in 2020
Peptilogics is developing eCAP technology, a propriety platform with preclinical effectiveness against resistant bacteria and biofilms. The company is dedicated to developing a new class of broad-spectrum antibiotics to address the epidemic of multidrug-resistant bacterial infections. Peptilogics is a preclinical biotechnology company with demonstrated preclinical in vitro and in vivo effectiness against the priority resistant pathogens.

Rational Vaccines

Series A in 2020
Rational Vaccines preclinical stage herpes vaccine development company actively working to improve lives with the hope of revolutionizing the treatment, prevention, and diagnosis of herpes and herpes-related diseases worldwide. Rational Vaccines was founded in 2015 and headquartered in Cambridge, Massachusetts.

Razor Group

Venture Round in 2020
Operator of a consumer goods holding company intended to invest and buy profitable brands. The company's marketplace combines advanced data analytics and custom-built technology, an optimized M&A process and in-house e-commerce and finance expertise to find suitable acquisition targets, enabling brands to scale profitable and demonstrate category leadership, better-quality products and customer reviews.

Razor Group

Venture Round in 2020
Operator of a consumer goods holding company intended to invest and buy profitable brands. The company's marketplace combines advanced data analytics and custom-built technology, an optimized M&A process and in-house e-commerce and finance expertise to find suitable acquisition targets, enabling brands to scale profitable and demonstrate category leadership, better-quality products and customer reviews.

Angiex

Venture Round in 2020
Angiex is a biotechnology company focused on developing vascular-targeted biotherapeutics for cancer treatment. Founded by leading scientists, the company specializes in antibody-drug conjugate therapies that address key aspects of endothelial biology, particularly angiogenesis. Angiex's lead product utilizes a novel approach to deliver therapeutic agents directly to the nucleus of tumor cells and to the activated endothelium of tumors and inflamed vessels. This innovative method aims to enhance the efficacy of treatments for various solid tumors, including pancreatic, lung, liver cancers, and glioblastoma multiforme. With intellectual property originating from Beth Israel Deaconess Medical Center, Angiex operates out of LabCentral in Cambridge, positioning itself at the forefront of cancer therapeutics.

Sensei Biotherapeutics

Series A in 2020
Sensei Biotherapeutics, Inc. develops precision cancer therapeutics that target a tumor-specific antigen (aspartate ß-hydroxylase). It offers various cancer immunotherapies, such as cancer vaccines and T-cell therapies for cancer patients. Sensei Biotherapeutics, Inc. was formerly known as Panacea Pharmaceuticals, Inc. The company was founded in 1999 and is based in Gaithersburg, Maryland with an additional office in Boston, Massachusetts.

Syfe

Series A in 2020
Syfe Pte. Ltd. is a digital investment manager based in Singapore that provides portfolio management, cash management, brokerage services, and wealth advisory. The firm focuses on creating customized, globally diversified portfolios for its clients by utilizing a proprietary algorithm that monitors and adjusts investments to optimize returns while managing risk. Syfe employs fundamental analysis to guide its investments in equity and fixed income markets worldwide. The platform aims to offer greater transparency and more efficient investment strategies, distinguishing itself from traditional investment management through the absence of high fees and hidden costs, ultimately striving for better investment outcomes for its clients.

Delix

Seed Round in 2020
Developer of clinical-stage neuroscience therapeutics intended to harness novel neuroplasticity-promoting treatments for difficult-to-treat neuropsychiatric and neurological disorders. The company's compounds include non-hallucinogenic, non-psychotomimetic, and non-dissociative versions of psychedelic components, enabling healthcare service providers to address significant mental health challenges through phenotypic drug discovery across various chemotypes and mechanisms of action.

Razor Group

Venture Round in 2020
Operator of a consumer goods holding company intended to invest and buy profitable brands. The company's marketplace combines advanced data analytics and custom-built technology, an optimized M&A process and in-house e-commerce and finance expertise to find suitable acquisition targets, enabling brands to scale profitable and demonstrate category leadership, better-quality products and customer reviews.

Penta

Series B in 2020
Penta Fintech Ltd. is a digital banking platform based in Berlin, Germany, specifically designed for startups and small to medium-sized enterprises (SMEs). Established in 2016, Penta aims to streamline banking processes for businesses by providing automated services such as bank account management and invoicing. The platform allows users to open a digital bank account quickly, typically within minutes, and offers cashless banking services that facilitate efficient cash flow management. With a mission to transform business banking in Europe and beyond, Penta focuses on helping its clients save time and money, thereby enhancing their overall banking experience.

Alloy Therapeutics

Series B in 2020
Alloy Therapeutics is a biotechnology company focused on enhancing drug discovery through accessible platforms and services. Founded in 2017 and based in Lexington, Massachusetts, the company offers Alloy-Gx, a comprehensive suite of immunocompetent transgenic mice that supports advanced human antibody discovery without royalty fees. This innovative platform aims to simplify and promote antibody discovery projects by providing broad, non-exclusive access to essential drug discovery tools. By democratizing these resources, Alloy Therapeutics enables scientists to pursue their antibody research more efficiently and effectively.

AbCellera

Series B in 2020
AbCellera Biologics Inc. is a biotechnology company that specializes in the discovery and development of therapeutic antibodies. Founded in 2012 and headquartered in Vancouver, Canada, it has created a full-stack, AI-powered platform that analyzes natural immune systems to identify antibodies suitable for drug development. The company employs next-generation transgenic mice, which generate fully human antibodies, enhancing its ability to discover effective therapeutic candidates. AbCellera's innovative approach addresses the limitations of traditional antibody discovery by enabling faster and more precise identification of optimal clinical candidates. It has established partnerships with various pharmaceutical companies, including a significant collaboration with Eli Lilly and Company to explore multiple targets. Through its proprietary technologies and expertise, AbCellera aims to streamline the antibody discovery process and support the development of next-generation therapeutics.

AbCellera

Series A in 2020
AbCellera Biologics Inc. is a biotechnology company that specializes in the discovery and development of therapeutic antibodies. Founded in 2012 and headquartered in Vancouver, Canada, it has created a full-stack, AI-powered platform that analyzes natural immune systems to identify antibodies suitable for drug development. The company employs next-generation transgenic mice, which generate fully human antibodies, enhancing its ability to discover effective therapeutic candidates. AbCellera's innovative approach addresses the limitations of traditional antibody discovery by enabling faster and more precise identification of optimal clinical candidates. It has established partnerships with various pharmaceutical companies, including a significant collaboration with Eli Lilly and Company to explore multiple targets. Through its proprietary technologies and expertise, AbCellera aims to streamline the antibody discovery process and support the development of next-generation therapeutics.

EnClear Therapies

Series A in 2020
EnClear Therapies, Inc. is a life sciences company based in Newburyport, Massachusetts, focused on developing device-based therapies for neurodegenerative diseases. The company specializes in the delivery and monitoring of cerebrospinal fluid (CSF) and has created a proprietary therapeutic platform aimed at removing toxic proteins from the CSF. EnClear's products are primarily designed to improve the lives of patients suffering from conditions such as Amyotrophic Lateral Sclerosis (ALS) and Progressive Supranuclear Palsy (PSP). By providing innovative solutions in the treatment of these neurological diseases, EnClear Therapies aims to help halt disease progression and extend patient lifespans.

Unmind

Series A in 2020
Unmind Ltd is a mental health platform based in London, United Kingdom, founded in 2016. It focuses on providing clinically-backed tools and training aimed at fostering healthier and happier workplaces. The platform is designed for businesses and includes a variety of features such as engaging learning and development programs created by industry experts, exercises addressing stress, focus, and sleep, as well as assessments that offer anonymized insights into employee well-being. Unmind's approach promotes positive cultural change within organizations by enabling employees to track and assess their mental health, while also providing secure support accessible from any device at any time.

Chemomab

Series C in 2019
ChemomAb Ltd. is a clinical-stage biopharmaceutical company based in Tel Aviv, Israel, founded in 2011. The company focuses on developing proprietary monoclonal antibodies aimed at treating autoimmune, inflammatory, and fibrotic diseases, including rare conditions. Its leading therapeutic candidate, CM-101, has undergone extensive pre-clinical testing in animal models that simulate human disorders, demonstrating promising safety and efficacy along with a novel mechanism of action. Through its innovative approach, ChemomAb aims to address unmet medical needs in immune-mediated and fibrotic disorders.

Deciduous Therapeutics

Venture Round in 2019
Deciduous Therapeutics is an aging therapeutics company developing a novel class of immune-modulatory therapies that clear senescent cells and promote a healthy lifespan. Deciduous is led by Anil Bhushan, a professor at UCSF, and Robin Mansukhani, a five-time biotech founder.

EnClear Therapies

Seed Round in 2019
EnClear Therapies, Inc. is a life sciences company based in Newburyport, Massachusetts, focused on developing device-based therapies for neurodegenerative diseases. The company specializes in the delivery and monitoring of cerebrospinal fluid (CSF) and has created a proprietary therapeutic platform aimed at removing toxic proteins from the CSF. EnClear's products are primarily designed to improve the lives of patients suffering from conditions such as Amyotrophic Lateral Sclerosis (ALS) and Progressive Supranuclear Palsy (PSP). By providing innovative solutions in the treatment of these neurological diseases, EnClear Therapies aims to help halt disease progression and extend patient lifespans.
Spot something off? Help us improve by flagging any incorrect or outdated information. Just email us at support@teaserclub.com. Your feedback is most welcome.